(Q36745408)

16 August 2017

1 reference

title

Graft-versus-leukemia in chronic lymphocytic leukemia (English)

1 reference

16 August 2017

0 references

1 reference

1

Ben-Bassat I

1 reference

16 August 2017

Raanani P

2

1 reference

16 August 2017

Gale RP

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

26 February 2007

1 reference

Bone Marrow Transplantation

16 August 2017

1 reference

16 August 2017

39

1 reference

16 August 2017

8

1 reference

16 August 2017

441-446

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705619

16 August 2017

0 references

cites work

Identical-twin bone marrow transplants for leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

Graft Versus Leukemia in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leuk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Cathepsin-B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Acute skin GVHD following syngeneic BMT for CLL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Graft-versus-host and graft-versus-leukemia reactions: a summary of the Seventh International Symposium held in Garmisch-Partenkirchen, Germany, February 22nd-25th, 2006, Tolerance and Immunity, an update on lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705619

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705619

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference